Welcome!

News Feed Item

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013


Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Macular Edema . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Macular Edema . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Diabetic Macular Edema 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Diabetic Macular Edema 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Diabetic Macular Edema Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Regeneron Pharmaceuticals, Inc. 38
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Alimera Sciences, Inc. 41
Clinical Trial Overview of Alimera Sciences, Inc. 41
Santen Pharmaceutical Co., Ltd. 42
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 42
Bausch & Lomb Incorporated 43
Clinical Trial Overview of Bausch & Lomb Incorporated 43
Clinical Trial Overview of Top Institutes / Government 44
Diabetic Retinopathy Clinical Research Network 44
Clinical Trial Overview of Diabetic Retinopathy Clinical Research Network 44
National Eye Institute 45
Clinical Trial Overview of National Eye Institute 45
Johns Hopkins University 46
Clinical Trial Overview of Johns Hopkins University 46
Shahid Beheshti University of Medical Sciences 47
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 47
The University of Sydney 48
Clinical Trial Overview of The University of Sydney 48
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Hong Kong Eye Hospital 51
Clinical Trial Overview of Hong Kong Eye Hospital 51
Federal University of Sao Paulo 52
Clinical Trial Overview of Federal University of Sao Paulo 52
University of Sao Paulo 53
Clinical Trial Overview of University of Sao Paulo 53
Five Key Clinical Profiles 54
Appendix 154
Abbreviations 154
Definitions 154
Research Methodology 155
Secondary Research 155
About GlobalData 155
Contact Us 155
Disclaimer 156
Source 156



List of Tables

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries, 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries, 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries, 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Diabetic Macular Edema Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Diabetic Macular Edema Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 35
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 37
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2013* 38
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 39
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2013* 40
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Alimera Sciences, Inc., 2013* 41
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Santen Pharmaceutical Co., Ltd., 2013* 42
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bausch & Lomb Incorporated, 2013* 43
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Diabetic Retinopathy Clinical Research Network, 2013* 44
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013* 45
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 46
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2013* 47
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2013* 48
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Moorfields Eye Hospital NHS Foundation Trust, 2013* 49
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2013* 50
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2013* 51
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2013* 52
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2013* 53



List of Figures

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 155


Read the full report:
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/treatments/diabetic_macular...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"A lot of times people will come to us and have a very diverse set of requirements or very customized need and we'll help them to implement it in a fashion that you can't just buy off of the shelf," explained Nick Rose, CTO of Enzu, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Who are you? How do you introduce yourself? Do you use a name, or do you greet a friend by the last four digits of his social security number? Assuming you don’t, why are we content to associate our identity with 10 random digits assigned by our phone company? Identity is an issue that affects everyone, but as individuals we don’t spend a lot of time thinking about it. In his session at @ThingsExpo, Ben Klang, Founder & President of Mojo Lingo, discussed the impact of technology on identity. Sho...
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
"Operations is sort of the maturation of cloud utilization and the move to the cloud," explained Steve Anderson, Product Manager for BMC’s Cloud Lifecycle Management, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.